{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T14:54:15Z","timestamp":1764168855293,"version":"3.46.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"DOI":"10.1186\/s13053-025-00325-8","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T14:49:23Z","timestamp":1764168563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics and healthcare burden of neurofibromatosis type 1 in Saudi Arabia: a single centre experience"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6057-9603","authenticated-orcid":false,"given":"Mohammed A.","family":"Almuqbil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha Al","family":"Ammari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada S.","family":"Al Dhayyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seena Thomas","family":"Kaithathara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Al Balwi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"325_CR1","doi-asserted-by":"crossref","unstructured":"Cimino PJ, Gutmann DH. Neurofibromatosis type 1. 2018. p. 799\u2013811.","DOI":"10.1016\/B978-0-444-64076-5.00051-X"},{"key":"325_CR2","doi-asserted-by":"crossref","unstructured":"Liao M, Lee HL, Liu YL, Wong TT. Neurofibromatosis type 1: a general review. J Korean Neurosurg Soc [Internet]. 2025. Available from: http:\/\/www.jkns.or.kr\/journal\/view.php?doi=10.3340\/jkns.2025.0073.","DOI":"10.3340\/jkns.2025.0073"},{"key":"325_CR3","doi-asserted-by":"crossref","unstructured":"Imataka G, Kuwashima S, Hayashi S, Ogino K, Hoshiyama E, Naruse K, et al. Neurofibromatosis type 1 and MEK inhibition: a comprehensive review with focus on selumetinib therapy. J Clin Med [Internet]. 2025;14(14):5071. Available from: https:\/\/www.mdpi.com\/2077-0383\/14\/14\/5071.","DOI":"10.3390\/jcm14145071"},{"issue":"1","key":"325_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnen\/64.1.1","volume":"64","author":"SL Carroll","year":"2005","unstructured":"Carroll SL, Stonecypher MS. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-Associated peripheral nerve sheath tumors. J Neuropathol Exp Neurol. 2005;64(1):1\u20139.","journal-title":"J Neuropathol Exp Neurol"},{"key":"325_CR5","doi-asserted-by":"crossref","unstructured":"Mo J, Moye SL, McKay RM, Le LQ. Neurofibromin and suppression of tumorigenesis: beyond the GAP. Oncogene [Internet]. 2022;41(9):1235\u201351. Available from: https:\/\/www.nature.com\/articles\/s41388-021-02156-y.","DOI":"10.1038\/s41388-021-02156-y"},{"issue":"1","key":"325_CR6","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Prim. 2017;3(1):17004.","journal-title":"Nat Rev Dis Prim"},{"issue":"1","key":"325_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2008.12.051","volume":"61","author":"KP Boyd","year":"2009","unstructured":"Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol. 2009;61(1):1.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"325_CR8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.7188\/bvsz.2023.99.5.3","volume":"99","author":"K Veres","year":"2023","unstructured":"Veres K, G\u00e1l AI, Fodor A, Garami M, Cs\u00f3ka M, Szalai ZZ. Recent advances in paediatric dermatology treatments: A summary. B\u0151rgy\u00f3gy\u00e1szati \u00e9s Venerol\u00f3giai Szle. 2023;99(5):342\u201354.","journal-title":"B\u0151rgy\u00f3gy\u00e1szati \u00e9s Venerol\u00f3giai Szle"},{"key":"325_CR9","doi-asserted-by":"crossref","unstructured":"Poplausky D, Young JN, Tai H, Rivera-Oyola R, Gulati N, Brown RM. Dermatologic manifestations of neurofibromatosis type 1 and emerging treatments. Cancers (Basel) [Internet]. 2023;15(10):2770. Available from: https:\/\/www.mdpi.com\/2072-6694\/15\/10\/2770.","DOI":"10.3390\/cancers15102770"},{"issue":"Supplement1","key":"325_CR10","doi-asserted-by":"publisher","first-page":"i33","DOI":"10.1093\/noajnl\/vdz037","volume":"2","author":"CJ Wei","year":"2020","unstructured":"Wei CJ, Gu SC, Ren JY, Gu YH, Xu XW, Chou X, et al. The impact of host immune cells on the development of neurofibromatosis type 1: the abnormal immune system provides an immune microenvironment for tumorigenesis. Neuro-Oncology Adv. 2020;2(Supplement1):i33\u20139.","journal-title":"Neuro-Oncology Adv"},{"issue":"1","key":"325_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1750-1172-7-75","volume":"7","author":"R Nguyen","year":"2012","unstructured":"Nguyen R, Dombi E, Widemann BC, Solomon J, Fuensterer C, Kluwe L, et al. Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. Orphanet J Rare Dis. 2012;7(1):75.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"325_CR12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/gim.2013.30","volume":"15","author":"R Nguyen","year":"2013","unstructured":"Nguyen R, Ibrahim C, Friedrich RE, Westphal M, Schuhmann M, Mautner VF. Growth behavior of plexiform neurofibromas after surgery. Genet Med. 2013;15(9):691\u20137.","journal-title":"Genet Med"},{"issue":"5","key":"325_CR13","doi-asserted-by":"publisher","first-page":"104734","DOI":"10.1016\/j.ejmg.2023.104734","volume":"66","author":"P Wolkenstein","year":"2023","unstructured":"Wolkenstein P, Chaix Y, Entz Werle N, Amini-Adle M, Barbarot S, Boileau C, et al. French cohort of children and adolescents with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas: CASSIOPEA study. Eur J Med Genet. 2023;66(5):104734.","journal-title":"Eur J Med Genet"},{"key":"325_CR14","doi-asserted-by":"crossref","unstructured":"Yu Y, Wei C, Yue M, Zhang C, Wang Y, Wang Z. From benign neurofibromas to malignant peripheral nerve sheath tumors (MPNST): a gaming among multiple factors. Cell Oncol [Internet]. 2025;48(4):841\u201357. Available from: https:\/\/link.springer.com\/10.1007\/s13402-025-01054-9.","DOI":"10.1007\/s13402-025-01054-9"},{"issue":"4","key":"325_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"325_CR16","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","volume":"23","author":"E Legius","year":"2021","unstructured":"Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021;23(8):1506\u201313.","journal-title":"Genet Med"},{"issue":"4","key":"325_CR17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1136\/ard.37.4.378","volume":"37","author":"WW Downie","year":"1978","unstructured":"Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Anderson JA. Studies with pain rating scales. Ann Rheum Dis. 1978;37(4):378\u201381.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"325_CR18","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","volume":"39","author":"JW Varni","year":"2001","unstructured":"Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the pediatric quality of life inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39(8):800\u201312.","journal-title":"Med Care"},{"key":"325_CR19","doi-asserted-by":"crossref","unstructured":"Maani N, Westergard S, Yang J, Scaranelo AM, Telesca S, Thain E, et al. NF1 patients receiving breast cancer screening: insights from the Ontario High Risk Breast Screening Program. Cancers (Basel) [Internet]. 2019;11(5):707. Available from: https:\/\/www.mdpi.com\/2072-6694\/11\/5\/707.","DOI":"10.3390\/cancers11050707"},{"key":"325_CR20","doi-asserted-by":"crossref","unstructured":"Scalzone M, Coccia P, Ruggiero A, Lazzareschi I, Mastrangelo S, Riccardi R. The neurofibromatosis type 1: a dominantly inherited tumors-predisposing disorder. Open Med [Internet]. 2009;4(1):11\u20136. Available from: https:\/\/www.degruyter.com\/document\/doi\/10.2478\/s11536-009-0013-x\/html.","DOI":"10.2478\/s11536-009-0013-x"},{"issue":"17","key":"325_CR21","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","volume":"34","author":"E Uusitalo","year":"2016","unstructured":"Uusitalo E, Rantanen M, Kallionp\u00e4\u00e4 RA, P\u00f6yh\u00f6nen M, Lepp\u00e4virta J, Yl\u00e4-Outinen H, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol. 2016;34(17):1978\u201386.","journal-title":"J Clin Oncol"},{"key":"325_CR22","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.2147\/JMDH.S454921","volume":"17","author":"M Almuqbil","year":"2024","unstructured":"Almuqbil M, Alshaikh FY, Altwaijri W, Baarmah D, Hommady RH, Alshaikh MY, et al. Epidemiology and outcomes of neurofibromatosis type 1 (NF-1): multicenter tertiary experience. J Multidiscip Healthc. 2024;17:1303\u201314.","journal-title":"J Multidiscip Healthc"},{"issue":"5","key":"325_CR23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.17712\/nsj.2020.5.20200081","volume":"25","author":"FA Bashiri","year":"2020","unstructured":"Bashiri FA, Alzamil LR, Aldhuwayhi RA. Clinical spectrum of neurofibromatosis type 1 among children in a tertiary care center. Neurosciences. 2020;25(5):375.","journal-title":"Neurosciences"},{"issue":"4","key":"325_CR24","first-page":"e37385","volume":"15","author":"MA Alfurayh","year":"2023","unstructured":"Alfurayh MA, Alawad NK, Akrish AM, Bin, Alharbi AS, Sharahili A, Saleem AS, Bin, et al. Phenotype and genotype of Saudi pediatric patients with neurofibromatosis type 1: A Seven-Year multicenter experience from Saudi Arabia. Cureus. 2023;15(4):e37385.","journal-title":"Cureus"},{"issue":"7\u2013S","key":"325_CR25","first-page":"101","volume":"91","author":"T Foiadelli","year":"2020","unstructured":"Foiadelli T, Naso M, Licari A, Orsini A, Magistrali M, Trabatti C, et al. Advanced Pharmacological therapies for neurofibromatosis type 1-related tumors. Acta Biomed. 2020;91(7\u2013S):101\u201314.","journal-title":"Acta Biomed"},{"issue":"1","key":"325_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13023-020-1310-3","volume":"15","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist C, Servy A, Valeyrie-Allanore L, Ferkal S, Combemale P, Wolkenstein P. Neurofibromatosis 1 French National guidelines based on an extensive literature review since 1966. Orphanet J Rare Dis. 2020;15(1):37.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"325_CR27","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","volume":"24","author":"MJ Fisher","year":"2022","unstructured":"Fisher MJ, Blakeley JO, Weiss BD, Dombi E, Ahlawat S, Akshintala S, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol. 2022;24(11):1827\u201344.","journal-title":"Neuro Oncol"},{"issue":"1","key":"325_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40487-022-00213-4","volume":"11","author":"C Ejerskov","year":"2023","unstructured":"Ejerskov C, Farholt S, Nielsen FSK, Berg I, Thomasen SB, Udupi A, et al. Clinical characteristics and management of children and adults with neurofibromatosis type 1 and plexiform neurofibromas in denmark: A nationwide study. Oncol Ther. 2023;11(1):97\u2013110.","journal-title":"Oncol Ther"},{"issue":"2","key":"325_CR29","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s10072-021-05361-5","volume":"43","author":"I Iheanacho","year":"2022","unstructured":"Iheanacho I, Yoo HK, Yang X, Dodman S, Hughes R, Amin S. Epidemiological and clinical burden associated with plexiform neurofibromas in pediatric neurofibromatosis type-1 (NF-1): a systematic literature review. Neurol Sci. 2022;43(2):1281\u201393.","journal-title":"Neurol Sci"},{"issue":"4","key":"325_CR30","doi-asserted-by":"publisher","first-page":"701","DOI":"10.4103\/idoj.idoj_569_23","volume":"15","author":"S Gorai","year":"2024","unstructured":"Gorai S, Rathore G, Das K. Selumetinib\u2014A comprehensive review of the new FDA-Approved drug for neurofibromatosis. Indian Dermatol Online J. 2024;15(4):701.","journal-title":"Indian Dermatol Online J"},{"issue":"26","key":"325_CR31","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, et al. Activity of selumetinib in neurofibromatosis type 1-Related plexiform neurofibromas. N Engl J Med. 2016;375(26):2550\u201360.","journal-title":"N Engl J Med"},{"issue":"15","key":"325_CR32","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382(15):1430\u201342.","journal-title":"N Engl J Med"},{"issue":"10","key":"325_CR33","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/jamadermatol.2024.2912","volume":"160","author":"MJ Lin","year":"2024","unstructured":"Lin MJ, Yao H, Vera K, Patel E, Johnson M, Caroline P, et al. Cutaneous neurofibromas and quality of life in adults with neurofibromatosis type 1. JAMA Dermatology. 2024;160(10):1091.","journal-title":"JAMA Dermatology"},{"issue":"06","key":"325_CR34","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1055\/s-0043-1768988","volume":"54","author":"S Hofmann","year":"2023","unstructured":"Hofmann S, Winkler S, Baumann M, Zellner H. Quality of life in children and adolescents with neurofibromatosis type 1: A Single-Center observational study. Neuropediatrics. 2023;54(06):430\u20132.","journal-title":"Neuropediatrics"},{"issue":"9","key":"325_CR35","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/ajmg.a.37123","volume":"167","author":"PL Wolters","year":"2015","unstructured":"Wolters PL, Burns KM, Martin S, Baldwin A, Dombi E, Toledo-Tamula MA, et al. Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social\u2010emotional functioning, and quality of life. Am J Med Genet Part A. 2015;167(9):2103\u201313.","journal-title":"Am J Med Genet Part A"},{"key":"325_CR36","doi-asserted-by":"crossref","unstructured":"Miller DT, Freedenberg D, Schorry E, Ullrich NJ, Viskochil D, Korf BR, et al. Health supervision for children with neurofibromatosis type 1. Pediatrics. 2019;143(5).","DOI":"10.1542\/peds.2019-0660"},{"key":"325_CR37","first-page":"421","volume":"11","author":"X Yang","year":"2020","unstructured":"Yang X, Desai K, Agrawal N, Mirchandani K, Chatterjee S, Sarpong E, et al. Treatment, resource use and costs among pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas. Pediatr Heal Med Ther. 2020;11:421\u20138.","journal-title":"Pediatr Heal Med Ther"},{"issue":"9","key":"325_CR38","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1080\/03007995.2021.1940907","volume":"37","author":"X Yang","year":"2021","unstructured":"Yang X, Desai K, Agrawal N, Mirchandani K, Chatterjee S, Sarpong E, et al. Characteristics, treatment patterns, healthcare resource use, and costs among pediatric patients diagnosed with neurofibromatosis type 1 and plexiform neurofibromas: a retrospective database analysis of a medicaid population. Curr Med Res Opin. 2021;37(9):1555\u201361.","journal-title":"Curr Med Res Opin"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-025-00325-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-025-00325-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-025-00325-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T14:49:28Z","timestamp":1764168568000},"score":1,"resource":{"primary":{"URL":"https:\/\/hccpjournal.biomedcentral.com\/articles\/10.1186\/s13053-025-00325-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["325"],"URL":"https:\/\/doi.org\/10.1186\/s13053-025-00325-8","relation":{},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was performed according to the guidelines of the Declaration of Helsinki and approved by the institutional review board at King Abdullah International Medical Research Center (KAIMRC), and the identifying number of the IRB approval was IRB\/0092\/24.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained from all participants prior to the face-to-face interviews.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}